I agree that this site is using cookies. You can find further informations here.
X
Strober, B
410  results:
Search for persons X
?
1

LB946 Spesolimab controls chronic inflammation in GPP:

Krueger, J.G. ; Gudjonsson, J.E. ; Morita, A....
Journal of Investigative Dermatology.  144 (2024)  8 - p. S165 , 2024
Link: https://doi.org/10.1016/..
 
?
2

Immunogenicity and pharmacokinetics of guselkumab among pat..:

Armstrong, A. ; Eyerich, K. ; Conrad, C....
Journal of the European Academy of Dermatology and Venereology.  37 (2023)  12 - p. , 2023
Link: https://doi.org/10.1111/..
 
?
3

Abrocitinib effect on patient‐reported outcomes in patients..:

Reich, K. ; Silverberg, J. I. ; Papp, K. A....
Journal of the European Academy of Dermatology and Venereology.  37 (2023)  10 - p. 2047-2055 , 2023
Link: https://doi.org/10.1111/..
 
?
4

A much needed metric: Defining reliable and statistically m..:

Strober, L.B. ; Bruce, J.M. ; Arnett, P.A....
Multiple Sclerosis and Related Disorders.  57 (2022)  - p. 103405 , 2022
Link: https://doi.org/10.1016/..
 
?
5

The Disease Burden of Generalized Pustular Psoriasis: Real-..:

Lebwohl, M ; Medeiros, R A. ; Mackey, R H....
Journal of Psoriasis and Psoriatic Arthritis.  7 (2022)  2 - p. 71-78 , 2022
Link: https://doi.org/10.1177/..
 
?
6

Super‐response to guselkumab treatment in patients with mod..:

Reich, K. ; Gordon, K.B. ; Strober, B....
Journal of the European Academy of Dermatology and Venereology.  36 (2022)  12 - p. 2393-2400 , 2022
Link: https://doi.org/10.1111/..
 
?
7

Long‐term, durable, absolute Psoriasis Area and Severity In..:

Gooderham, M. ; Pinter, A. ; Ferris, L.K....
Journal of the European Academy of Dermatology and Venereology.  36 (2022)  6 - p. 855-865 , 2022
Link: https://doi.org/10.1111/..
 
?
8

Effect of baseline disease severity on achievement of treat..:

Reich, K. ; Mrowietz, U. ; Menter, A....
Journal of the European Academy of Dermatology and Venereology.  35 (2021)  12 - p. 2409-2414 , 2021
Link: https://doi.org/10.1111/..
 
?
9

Efficacy and safety of apremilast in patients with moderate..:

Van Voorhees, A.S. ; Stein Gold, L. ; Lebwohl, M....
British Journal of Dermatology.  185 (2021)  4 - p. 840-842 , 2021
Link: https://doi.org/10.1111/..
 
?
10

Bimekizumab Safety in Patients with Moderate to Severe Psor..:

Reich, K ; Blauvelt, A ; Lebwohl, M...
SKIN The Journal of Cutaneous Medicine.  5 (2021)  1 - p. s21 , 2021
Link: https://doi.org/10.25251..
 
?
11

Bimekizumab versus Ustekinumab Efficacy Across Subgroups of..:

Strober, B ; Krueger, JG ; Magnolo, N...
SKIN The Journal of Cutaneous Medicine.  5 (2021)  1 - p. s16 , 2021
Link: https://doi.org/10.25251..
 
?
12

Tired of not knowing what that fatigue score means? Normati..:

Strober, L.B. ; Bruce, J.M. ; Arnett, P.A....
Multiple Sclerosis and Related Disorders.  46 (2020)  - p. 102576 , 2020
Link: https://doi.org/10.1016/..
 
?
13

BMS-986165, un inhibiteur oral sélectif de la tyrosine kina..:

Strober, B. ; Gottlieb, A. ; Thaçi, D....
Annales de Dermatologie et de Vénéréologie.  147 (2020)  12 - p. A355-A356 , 2020
Link: https://doi.org/10.1016/..
 
?
14

Efficacy of risankizumab in patients with moderate‐to‐sever..:

Strober, B. ; Menter, A. ; Leonardi, C....
Journal of the European Academy of Dermatology and Venereology.  34 (2020)  12 - p. 2830-2838 , 2020
Link: https://doi.org/10.1111/..
 
?
15

Efficacité d'upadacitinib chez des patients atteints de rhu..:

Mease, P.J. ; Lertratanakul, A. ; Strober, B....
Revue du Rhumatisme.  87 (2020)  - p. A31-A32 , 2020
Link: https://doi.org/10.1016/..
 
1-15